搜索
Valneva SE
VALN添加自选
5.225USD
+0.135+2.65%
收盘 07/02, 13:00（美东）报价延迟15分钟
453.93M总市值
亏损市盈率 TTM
关键数据
5.275今开
5.430最高
19.02K成交量
亏损市盈率 TTM
7.49市盈率动
--股息TTM
0.02%换手率
5.090昨收
5.160最低
74.53K成交额
亏损市盈率静
5.04市净率
0.00%股息率 TTM
-32.32%ROA
12.25052周最高
1.17量比
-12.25M净利润
86.88M总股本
-1.3936每股收益TTM
1.75Beta
-109.57%ROE
5.06052周最低
5.30%振幅
15.29%毛利率
453.93M总市值
-4.12回报/风险
2.48%风险率
TradingKey Valneva SE股票评分
单位: USD 更新时间: 2026-07-02操作建议
Valneva SE当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名129/387位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价12.20。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Valneva SE评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Valneva SE亮点
亮点风险
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
业绩高增长
公司营业收入稳步增长，连续3年增长33.76%
利润高增长
公司净利润处于行业前列，最新年度总收入205.61M美元
估值高估
公司最新PE估值-3.75，处于3年历史高位
机构减仓
最新机构持股5.21M股，环比减少5.60%
活跃度降低
近期活跃度降低，过去20天平均换手率-0.57
分析师目标
根据
4
位分析师
买入
评级
12.200
目标均价
+139.69%
涨幅空间
Valneva SE新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Valneva SE简介
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
公司代码VALN
公司Valneva SE
CEOLingelbach (Thomas)
网址https://valneva.com/
相关品种
热门品种
常见问题
Valneva SE(VALN)的当前股价是多少？
Valneva SE(VALN)的当前股价是 5.22。
Valneva SE的股票代码是什么？
Valneva SE的股票代码是VALN。
Valneva SE股票的52周最高点是多少？
Valneva SE股票的52周最高点是12.25。
Valneva SE股票的52周最低点是多少？
Valneva SE股票的52周最低点是5.06。
Valneva SE的市值是多少？
Valneva SE的市值是453.93M。
现在Valneva SE(VALN)的股票是买入、持有还是卖出？
根据分析师评级，Valneva SE(VALN)的总体评级为买入，目标价格为12.20。
Valneva SE(VALN)股票的每股收益（EPS TTM）是多少
Valneva SE(VALN)股票的每股收益（EPS TTM）是-1.61。